References
- Moeller FG, Barratt ES, Dougherty DM, Schmitz JM, Swann AC. Psychiatric aspects of impulsivity. Am. J. Psychiatry158(11), 1783–1793 (2001).
- Dickman SJ. Functional and dysfuncitional impulsivity: personality and cognitive correlates. J. Pers. Soc. Psychol.58, 95–102 (1990).
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. American Psychiatric Association, DC, USA (2005).
- WHO. The ICD Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization, Geneva, Switzerland (2000).
- Zuckerman M. P-impulsive sensation seeking and its behavioral, psychophysiological and biochemical correlates. Neuropsychobilogy28(1–2), 30–36 (1993).
- Kertzman S, Grinspan H, Birger M, Kotler M. Computerized neuropsychological examination of impulsiveness: a selective review. Isr. J. Psychiatry Relat. Sci.43(2), 74–80 (2010).
- Baud P. Personality traits as intermediary phenotypes in suicidal behavior: genetic issues. Am. J. Med. Genet. C Semin. Med. Genet.133C(1), 34–42 (2005).
- Mann JJ. A current perspective of suicide and attempted suicide. Ann. Intern. Med.136, 302–311 (2002).
- Mann JJ. The biology of impulsivity and suicidality. Psychiatr. Clin. North Am.23(1), 11–25 (2000).
- Siever LJ. Neurobiology of aggression and violence. Am. J. Psychiatry165(4), 429–442 (2008).
- Dalley JW, Marc AC, Economidou D, Robbins TW. Neurobehavioral mechanisms of impulsivity: fronto–striatal systems and functional neurochemistry. Pharmacol. Biochem. Behav.90(2), 250–260 (2008).
- Sher L, Stanley B. The role of endogenous opioids in the pathophysiology of self-injurious and suicidal behavior. Arch. Suicide Res.12(4), 299–308 (2008).
- Braquehais MD, Oquendo MA, Baca-García E, Sher L. Is impulsivity a link between childhood abuse and suicide? Compr. Psychiatry51(2), 121–129 (2010).
- Siever LJ, Buchsbaum MS, New AS. D,l-Fenfluramine response in impulsivity personality disorders assessed with 18-F-Fluorodeoxyglucose positron emission tomography. Neuropsychopharmacology20, 413–423 (1999).
- Friedel RO. Dopamine dysfunction in borderline personality disorder: a hypothesis. Neuropsychopharmacology29(6), 1029–1039 (2004).
- Gobbi G, Janiri L. Sodium- and magnesium-valproate in vivo modulate glutamatergic and GABAergic synapses in the medial prefrontal cortex. Psychopharmacology (Berl.)185(2), 255–262 (2006).
- Lafenêtre P, Chaouloff F, Marsicano G. Bidirectional regulation of novelty-induced behavioral inhibition by the endocannabinoid system. Neuropharmacology57(7–8), 715–721 (2009).
- Marco EM, Adriani W, Canese R, Podo F, Viveros MP, Laviola G. Enhancement of endocannabinoid signalling during adolescence: modulation of impulsivity and long-term consequences on metabolic brain parameters in early maternally deprived rats. Phramacol. Biochem. Behav.86(2), 334–345 (2007).
- Stanley B, Siever LJ. The interpersonal dimension of borderline personality disorder: toward a neuropeptide model. Am. J. Psychiatry167(1), 24–39 (2010).
- Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of pharmacotherapies for borderline personality disorder. CNS Drugs22(8), 671–692 (2008).
- Ramos-Quiroga JA, Corominas M, Castells X, Bosch R, Casas M. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder. Expert Rev. Neurother.9(8), 1121–1131 (2009).
- Oades RD. Role of the serotonin system in ADHD: treatment implications. Expert Rev. Neurother.7(10), 1357–1374 (2007).